The NxStage Therapy System is indicated for treatment of renal failure or fluid overload using hemofiltration and/or ultrafiltration. The NxStage Cartridge Express is part of the NxStage Therapy System and is intended for use with the NxStage Cycler.

Device Description

The NxStage Cartridge Express is an extracorporeal blood tubing set with preconnected high flux (permeability) hollow-fiber filter.

AI/ML Overview

The provided text describes the NxStage Cartridge Express, a medical device, and its regulatory clearance. However, it does not contain the specific information requested regarding acceptance criteria and a study proving the device meets those criteria, as typically seen for AI/ML-based devices.

Here's why the requested information cannot be extracted from the provided text:

Device Type: The NxStage Cartridge Express is described as an "extracorporeal blood tubing set with preconnected high flux (permeability) hollow-fiber filter," which is a physical medical device, not an AI/ML algorithm or system.
Study Details: The document explicitly states "Clinical Data: Not applicable" and refers to "in vitro testing" to characterize performance and establish substantial equivalence to predicate devices. This type of testing for a physical device focuses on performance characteristics (e.g., filtration rates, biocompatibility), not on metrics like sensitivity, specificity, or reader improvement seen in AI/ML studies.
Acceptance Criteria for AI/ML: The concepts of "acceptance criteria," "test set," "ground truth," "expert consensus," "MRMC studies," "standalone performance," and "training set" are primarily relevant to the validation of AI/ML algorithms, not to the in vitro testing of a physical hemifilter.

Therefore, I cannot provide the requested information in the format specified because it is not present in the provided document, as the device is not an AI/ML product.

The summary states:

Summary of Non-clinical Test: "In vitro testing was conducted to characterize performance of the NxStage Hemofilter to provide a basis of comparison to the predicate devices. Results of in vitro studies have documented that the NxStage Cartridge Express is substantially equivalent to the predicate devices and is suitable for the intended use specified."
Clinical Data: "Not applicable"

This indicates that the clearance was based on non-clinical, in-vitro testing demonstrating substantial equivalence to predicate devices, rather than a clinical study with detailed performance metrics against specific acceptance criteria for AI algorithms.

Summary

{0}------------------------------------------------

178

510(k) Summary for the NxStage Cartridge Express Page 1 of 2

DEC 11 2002

Submitter's Name and Address:	NxStage Medical Inc.439 Union StreetLawrence, MA 01483
Phone Number:	978-687-4700
Telefax Number:	978-687-4800
Contact Person:	Karen St. Onge, Director Quality Assuranceand Regulatory Affairs
Date Summary Prepared:	December 17, 2001
Device Trade Name:	NxStage Cartridge Express
Common name:	Extracorporeal Blood Circuit w/ Hemofilter
Classification Name:	High Permeability Hemodialysis System (21CFR 876.5860)
Substantial Equivalence:	The proposed device is substantiallyequivalent to other legally marketedhemofilters/hemodialyzers previouslycleared by the FDA via the 510(k)Notification process such as the SYNTRADialyzer (Baxter Healthcare Corporation,K002210), Cobe Arylane Hemodialyzer(Gambro Healthcare, K982414), Renoflo® IIHemofilter (Minntech Corp, K923312) and tothe Prisma CFM System hemofilter (HospalRenal Intensive Care, K942679) alsoprovided preconnected to the hemofiltrationsystem disposable tubing set.
Device Description:	The NxStage Cartridge Express is anextracorporeal blood tubing set withpreconnected high flux (permeability)hollow-fiber filter.
Intended Use:	For treatment of renal failure or fluidoverload using hemofiltration and/orultrafiltration.
Technological Characteristics:	The proposed device has the sametechnological characteristics and is similarin design and configuration compared withthe predicate devices.

lxStage Cartridge Ex
1 of 2

{1}------------------------------------------------

KO14152

2/2

510(k) Summary for the NxStage Cartridge Express Page 2 of 2

Summary of Non-clinical Test:	In vitro testing was conducted tocharacterize performance of the NxStageHemofilter to provide a basis of comparisonto the predicate devices. Results of in vitrostudies have documented that the NxStageCartridge Express is substantially equivalentto the predicate devices and is suitable forthe intended use specified.
-------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical Data:

Not applicable

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image contains the text "Public Health Service" in a simple, sans-serif font. The text is black and appears to be the only element in the image. The words are stacked on top of each other, with "Public Health" on the top line and "Service" on the bottom line.

ood and Drug Administration 200 Corporate Boulevard Rockville MD 20850

Ms. Norma LeMay Senior Regulatory Affairs Specialist NxStage Medical, Inc. 439 South Union Street 5th Floor LAWRENCE MA: 01843

Re: K014152

Trade/Device Name: NxStage Cartridge Express Regulation Number: 21 CFR 8876.5860 Regulation Name: High permeability hemodialysis ·· svstem Regulatory Class: II Product Code: 78 KDI Dated: September 11, 2002 Received: September 12, 2002

Dear Ms. LeMay:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device.on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876:2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Nancy C Brogdon

Nancy C. Brogdon Director. Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K014152

Device Name: NxStage Cartridge Express

Indications for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Daniel A. Seggern

Prescription Use

Over-The-Counter

Use

(Per 21 CFR 801.109)

Regulation Number and Section

§ 876.5860 High permeability hemodialysis system.

(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”